EG 427
Developer of a pinpoint gene therapy designed to cure spinal cord injury-related disorders. The company develops HSV-1-based vectors by exploiting the natural properties of Herpes Simplex Virus 1 (HSV...
Valuation
$123.9M
Latest known
Share Price
N/A
Total Raised
$48.9M
Last Round
N/A